Active Ingredient History

  • Now
Selurampanel is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.   Wikipedia

  • SMILES: CC(C)c1cc2NC(=O)N(NS(=O)(=O)C)C(=O)c2cc1c3ccnn3C
  • Mol. Mass: 377.43
  • ALogP: 0.72
  • ChEMBL Molecule:
More Chemistry
bgg492 | bgg-492 | selurampanel


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue